Cure51
Latest round
- Seed
Last raised
- Mar 2024
Total raised
- $8.2M
Investors
- 4
About Cure51
Founded in 2021 and based in Paris, France, Cure51 operates as a provider of a database for cancer survivors to examine causes and cures. Nicolas Wolikow (CEO) and Simon Istolainen (CSO) are the co-founders of the company. The company provides its discovery platform, which is a system designed to organize, analyze, and discover therapeutic targets. The firm’s platform builds a comprehensive clinical and multi-omics database of outliers worldwide. Cure51 discovers multimodal signs and develops medicine tools that provide actionable insights for therapeutic discovery in partnership with scientific partners and computational biology.
Who invested in Cure51
4 investors across 1 round
See all investors in Cure51
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Mar 14, 2024
Amount
$8.2M
Investors
Questions about Cure51
Who invested in Cure51?
Cure51 has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cure51 raised?
Cure51 has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cure51 last raise money?
Cure51's most recent round on record is a Seed, in Mar 2024.
What does Cure51 do?
Founded in 2021 and based in Paris, France, Cure51 operates as a provider of a database for cancer survivors to examine causes and cures.
Where is Cure51 headquartered?
Cure51 is headquartered in Paris, France.
Which VCs invest in companies like Cure51?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Cure51's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Cure51? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.